Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

22 of 40

Peter Mueller, Executive Vice President for R&D at Vertex Pharmaceuticals

Big Pharma first grew enamored with China for its arbitrage opportunities: Cheap labor, abundant resources and manageable regulations. Now, however, the country is churning out Ph.D.s faster than the U.S., and its incoming government wants to transform China into a knowledge-based economy. Peter Mueller, Vertex's executive vice president for R&D, said we're on the verge of a golden age in Chinese pharma innovation, and his company has gone from looking to the country for manufacturing to partnering with its universities, contractors and drugmakers to better develop treatments suited to its unique and diverse population.